US 12,202,849 B2 · Crystalline forms of tenofovir alafenamide

Abstract

The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.

Claims22

Dependent claims

Crystalline Tenofovir Alafenamide Napsylate Form I, characterized by an X-ray powder diffraction (XRPD) pattern having peaks at about 3.9°, 7.8°, 13.6°, 15.3°, and 19.2° 2-θ±0.2° 2-θ.

Dependencies are inferred from the claim text.

Facts

Application

17/885,883Filed 11 Aug 2022 · continuation

Priority

31 Jan 2017

Published

US 2023/0091736 A123 Mar 2023

Granted

21 Jan 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07F 9/65616
Containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system,…:…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/675
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Family

Application62/452,428Us provisional application · filed 31 Jan 2017

Application15/882,784Parent of this division · filed 29 Jan 2018

Application16/360,763Parent of this continuation · filed 21 Mar 2019

US 10,287,307 B2Parent of this division · filed 14 May 2019

US 2023/0091736 A1Pre-grant publication · published 23 Mar 2023

US 11,440,928 B2Parent of this continuation

Application16/360,763Parent of this division

US 2018/0265530 A1Published application

US 2019/0233448 A1Published application

US 12,202,849 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

17/885,883Filed 11 Aug 2022 · continuation

Priority

31 Jan 2017

Published

US 2023/0091736 A123 Mar 2023

Granted

21 Jan 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07F 9/65616
Containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system,…:…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/675
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Family

Application62/452,428Us provisional application · filed 31 Jan 2017

Application15/882,784Parent of this division · filed 29 Jan 2018

Application16/360,763Parent of this continuation · filed 21 Mar 2019

US 10,287,307 B2Parent of this division · filed 14 May 2019

US 2023/0091736 A1Pre-grant publication · published 23 Mar 2023

US 11,440,928 B2Parent of this continuation

Application16/360,763Parent of this division

US 2018/0265530 A1Published application

US 2019/0233448 A1Published application

US 12,202,849 B2This patent

From the US filing history. Foreign family members aren’t listed.

Crystalline forms of tenofovir alafenamide

Life of this patent

Abstract

Claims22

Crystalline forms of tenofovir alafenamide

Life of this patent

Abstract

Claims22